China-based heart valve company Venus Medtech (Hangzhou) has entered into an agreement to buy Israeli medical device firm Keystone Heart for an undisclosed amount.

The deal will primarily provide Venus Medtech with international rights to Keystone Heart’s cerebral embolic protection device TriGUARD 3.

TriGUARD 3 offers complete coverage to all three major cerebral branches in order to protect from emboli during cardiovascular procedures.

“The acquisition, subject to customary closing conditions, is expected to be completed in the fourth quarter of this year.”

Embolic brain lesions may result in stroke, dementia and cognitive decline, and the cerebral embolic protection device is intended to minimise the risk of such brain damage.

Besides the addition of the device, the acquisition is also expected to support Venus Medtech’s foray into the US and EMEA regions.

Venus Medtech co-founder and CEO Eric Zi said: “Our transcatheter heart valve systems offer patients life-saving support. Acquiring Keystone Heart allows us the opportunity not only to reduce the risk of brain injury during cardiac procedures but establishes our presence in the US and EMEA through which we can introduce our entire portfolio of products.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Keystone Heart focuses on the protection of the brain from emboli to minimise the risk of brain infarcts in structural heart procedures such as TAVR, surgical valve replacement and atrial fibrillation ablation.

Currently, the firm is conducting enrolment of patients for the prospective, randomised REFLECT trial in the US to assess the safety and efficacy TriGUARD 3.

Initiated in June this year, the trial is expected to conclude enrolment in the first quarter of next year.

Keystone Heart president and CEO Chris Richardson said: “This partnership provides us the unique opportunity to improve the lives of patients undergoing structural heart procedures with cerebral embolic protection and the ability of bringing new cutting-edge therapies into the US & EMEA.”

The acquisition, subject to customary closing conditions, is expected to be completed in the fourth quarter of this year.